Botanix Pharmaceuticals Limited

As of June 30, 2026, Botanix Pharmaceuticals Limited carries a market capitalization of 51.95M, placing it among publicly traded companies globally. Its enterprise value stands at 41.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Botanix Pharmaceuticals Limited's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2026, Botanix Pharmaceuticals Limited has 2.73B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.22, and the price-to-book ratio stands at 0.82.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 41.09M versus a market cap of 51.95M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Botanix Pharmaceuticals Limited maintains a current ratio of 2.59, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.57, indicating elevated leverage, while an interest coverage ratio of -23.61 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Botanix Pharmaceuticals Limited posted a negative return on equity (ROE) of -96.35, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -59.36, reflecting losses generated across the asset base. The company generates approximately 1.02M in revenue per employee across its workforce of 33.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.48 indicates how many times Botanix Pharmaceuticals Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Botanix Pharmaceuticals Limited's stock has declined approximately 91.03% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.04.

Over the twelve months ended June 30, 2026, Botanix Pharmaceuticals Limited generated 33.80M in revenue and converted that into -69.77M in net income, yielding earnings per share of -0.03. EBITDA reached -66.99M, while operating income came in at -69.31M.

As of June 30, 2026, Botanix Pharmaceuticals Limited holds 36.63M in cash and equivalents against 25.77M in total debt, resulting in a net debt position of -11.78M. Total book value stands at 63.52M, with working capital of 49.30M providing operational flexibility.

Over the twelve months ended June 30, 2026, Botanix Pharmaceuticals Limited posted a gross margin of 57.61, reflecting its pricing power and cost economics. The operating margin of -205.05 and net profit margin of -206.41 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -70.40, meaning Botanix Pharmaceuticals Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Botanix Pharmaceuticals Limited's most recent stock split took place on July 15, 2016 with a 10:3 split ratio.

As of June 30, 2026, Botanix Pharmaceuticals Limited has an Altman Z-Score of -5.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.